PETX earnings call for the period ending December 31, 2018.
News & Analysis: Aratana Therapeutics
Shares fall hard in response to an analyst downgrade. Here's what investors need to know.
The S&P 500's top-performing stock last year and two under-the-radar small caps could be worth a closer look.
Two specialized small-cap drug developers, and a financial holding company share similar traits to software giant Microsoft from three decades ago.
What sent these stocks lower on a strong market day?
Shares tumble after the company announces that it is tapping shareholders for cash.
Looking for a few biotech stocks that have upside potential? Here's why our investors think you should check out Edge Therapeutics, Aratana Therapeutics, and Alkermes.
It's best to wait until the price is right.
Shares drop after the company reported disappointing fourth-quarter sales.
Shares fall in response to news of a delayed product launch.